U. E. K. Wolf-Schnurrbusch
University of Bern
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by U. E. K. Wolf-Schnurrbusch.
Diabetes Care | 2010
Pascale Massin; Francesco Bandello; Justus G. Garweg; Lutz L. Hansen; Simon P. Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U. E. K. Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf
OBJECTIVE The expression of vascular endothelial growth factor (VEGF) is elevated in diabetic macular edema (DME). Ranibizumab binds to and inhibits multiple VEGF variants. We investigated the safety and efficacy of ranibizumab in DME involving the foveal center. RESEARCH DESIGN AND METHODS This was a 12-month, multicenter, sham-controlled, double-masked study with eyes (age >18 years, type 1 or 2 diabetes, central retinal thickness [CRT] ≥300 μm, and best corrected visual acuity [BCVA] of 73–39 ETDRS letters [Early Treatment Diabetic Retinopathy Study]) randomly assigned to intravitreal ranibizumab (0.3 or 0.5 mg; n = 51 each) or sham (n = 49). The treatment schedule comprised three monthly injections, after which treatment could be stopped/reinitiated with an opportunity for rescue laser photocoagulation (protocol-defined criteria). After month 1, dose-doubling was permitted (protocol-defined criteria, injection volume increased from 0.05 to 0.1 ml and remained at 0.1 ml thereafter). Efficacy (BCVA and CRT) and safety were compared between pooled ranibizumab and sham arms using the full analysis set (n = 151, patients receiving ≥1 injection). RESULTS At month 12, mean ± SD BCVA improved from baseline by 10.3 ± 9.1 letters with ranibizumab and declined by 1.4 ± 14.2 letters with sham (P < 0.0001). Mean CRT reduction was 194.2 ± 135.1 μm with ranibizumab and 48.4 ± 153.4 μm with sham (P < 0.0001). Gain of ≥10 letters BCVA from baseline occurred in 60.8% of ranibizumab and 18.4% of sham eyes (P < 0.0001). Safety data were consistent with previous studies of intravitreal ranibizumab. CONCLUSIONS Ranibizumab is effective in improving BCVA and is well tolerated in DME. Future clinical trials are required to confirm its long-term efficacy and safety.
Investigative Ophthalmology & Visual Science | 2009
U. E. K. Wolf-Schnurrbusch; Lala Ceklic; C. K. Brinkmann; Milko E Iliev; Manuel Frey; S. P. Rothenbuehler; Volker Enzmann; Sebastian Wolf
PURPOSE To compare central retinal thickness (CRT) measurements in healthy eyes by different commercially available OCT instruments and to compare the intersession reproducibility of such measurements. METHODS Six different OCT instruments (Stratus OCT [Carl Zeiss Meditec, Inc. Dublin, CA], SOCT Copernicus [Reichert/Optopol Technology, Inc., Depew, NY], Spectral OCT/SLO [Opko/OTI, Inc., Miami, FL], RTVue-100 [Optovue Corp., Fremont, CA], Spectralis HRA+OCT [Heidelberg Engineering, Inc., Heidelberg, Germany], and Cirrus HD-OCT [Carl Zeiss Meditec, Inc.]) were used to assess CRT in both eyes of healthy subjects. Measurements were performed in two different sessions on the same day with each of the systems. From these measurements, the mean CRT was calculated. For the assessment of the intersession reproducibility of the instruments, we calculated the coefficient of the variation of test-retest variation. RESULTS Twenty healthy subjects were included in the study. Compared with the Stratus OCT all spectral OCT instruments showed significantly higher CRTs. The Spectralis HRA+OCT and Cirrus HD-OCT showed similar CRT values but significantly higher values than did all other instruments. The coefficients of variation for repeated measurements was 3.33% for the Stratus OCT, 0.46% for the Spectralis HRA+OCT, 3.09% for the Cirrus HD-OCT, 2.23% for the OCT/SLO, 2.77% for the RTVue-100 OCT, and for the SOCT 3.5%, respectively. discussion. The six OCT systems provided different results for CRT. The measurements with the Stratus OCT showed the lowest thicknesses, whereas those with the Cirrus HD-OCT and Spectralis HRA+OCT yielded the highest ones. These discrepancies can be explained by the differences in the retinal segmentation algorithms used by the various OCT systems. Whereas the Spectralis HRA+OCT and Cirrus HD-OCT include the RPE layer in the retinal segmentation, the other instruments do not. The data imply that the different OCT systems cannot be used interchangeably for the measurement of macular thickness.
Investigative Ophthalmology & Visual Science | 2009
Sebastian Wolf; Pascale Massin; Francesco Bandello; D. Sharp; Paolo Lanzetta; Michael Larsen; U. E. K. Wolf-Schnurrbusch; Margarita Gekkieva
Investigative Ophthalmology & Visual Science | 2009
U. E. K. Wolf-Schnurrbusch; Sebastian Wolf; D. Völker; C. K. Brinkmann; S. P. Rothenbuehler; François C. Delori
Investigative Ophthalmology & Visual Science | 2010
Volker Enzmann; Roberto Hess; F. Jordi; Sebastian Wolf; U. E. K. Wolf-Schnurrbusch
Investigative Ophthalmology & Visual Science | 2009
C. K. Brinkmann; S. P. Rothenbuehler; U. E. K. Wolf-Schnurrbusch; Sebastian Wolf
Investigative Ophthalmology & Visual Science | 2017
Ferenc B. Sallo; Irene Leung; U. E. K. Wolf-Schnurrbusch; Bingqian Liu; Kiyoko Gocho; Valérie Krivosic; Tunde Peto; Daniel Pauleikhoff; Traci E. Clemons; Michel Paques; Emily Y. Chew; A. Gaudric; Alan C. Bird
Diabetes Care | 2011
P Massini; Francesco Bandello; Jg Garweg; Ll Hansen; Simon P. Harding; Michael Larsen; Paul Mitchell; Dianne Sharp; U. E. K. Wolf-Schnurrbusch; Margarita Gekkieva; Andreas Weichselberger; Sebastian Wolf
Investigative Ophthalmology & Visual Science | 2010
S. P. Rothenbuehler; U. E. K. Wolf-Schnurrbusch; Sebastian Wolf
Investigative Ophthalmology & Visual Science | 2010
Sebastian Wolf; R. Ruehl; Carsten Framme; U. E. K. Wolf-Schnurrbusch